committee. The applicant will be responsible for providing assurance in accordance with the appropriate guidelines and forms provided in the application kit. Should human subjects reviews be required, the proposed word play should incorporate timelines for such development and review activities.

Women, Racial, and Ethnic Minorities Policy

It is the policy of the CDC to ensure that women and racial and ethnic groups will be included in CDC-supported research projects involving human subjects, whenever feasible and appropriate. Racial and ethnic groups are those defined in OMB Directive No. 15 and include American Indian or Alaskan Native, Asian, Black or African American, Native Hawaiian or Other Pacific Islander, and Hispanic or Latino. Applicants shall ensure that women and racial and ethnic minority populations are appropriately represented in applications for research involving human subjects. Where clear and compelling rationale exist that inclusion is not feasible, this situation must be explained as part of the application. In conducting the review of applications for scientific merit, review groups will evaluate proposed plans for inclusion of minorities and both sexes as part of the scientific assessment and assigned score. This policy does not apply to research studies when the investigator cannot control the race, ethnicity and/or sex of subjects. Further guidance to this policy is contained in the **Federal Register**, Vol. 60, No. 179, Friday, September 15, 1995, pages 47947–47951.

Confidentiality

Any personal identifying information obtained in connection with the delivery of services provided to any individual under any program that is being carried out with a cooperative agreement made under this Program Announcement shall not be disclosed unless required by a law of a State or political subdivision or unless such an individual provides written, voluntary informed consent.

Application Submission and Deadline

The application must be carefully completed, following the directions provided in this Program Announcement. An original and two copies of the application PHS Form 5161–1 (Revised 5/96) must be submitted to Sharron P. Orum, Grants Management Officer, Procurement and Grants Office, Centers for Disease Control and Prevention, (CDC), 255 East Paces Ferry Road, NE., Mailstop E–18, Atlanta, GA 30305–2209, on or before August 14, 1998.

1. Deadline: Applications shall be considered as meeting the deadline if they are either:

a. Received on or before the deadline date; or

b. Sent on or before the deadline date and received in time for submission to the objective review group. (Applicants must request a legibly dated U.S. Postal Service postmark or obtain a legibly dated receipt from a commercial carrier or U.S. Postal Service. Private metered postmarks shall not be acceptable as proof of timely mailing.)

2. Late Applications: Applications that do not meet the criteria in 1.a. and 1.b. above are considered late applications. Late applications will not be considered in the current competition and will be returned to the applicant.

Where To Obtain Additional Information

A complete program description and information on application procedures are contained in the application package. Business management technical assistance may be obtained from Locke Thompson, Grants Management Specialist, Grants Management Branch, Procurement and Grants Office, Centers for Disease Control and Prevention (CDC), 255 East Paces Ferry Road, NE., Room 300, Mailstop E–18, Atlanta, GA 30305–2209, telephone (404) 842–6595; fax (404) 842–6513; or Internet or CDC WONDER E-mail at <lxt1@.cdc.gov>. Programmatic technical assistance may be obtained from Bernice A. Moore, Epidemiology and Statistics Branch, Division of Diabetes Translation, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention (CDC), Mailstop K–10, 4770 Buford Highway NE., Atlanta, GA 30341–3701, telephone (770) 488–5855; fax (770) 488–5966; or Internet or CDC WONDER E-mail at <bamo@cdc.gov>.

To receive additional written information and to request an application kit, call 1–888–GRANTS4 (1–888–472–6874). You will be asked to leave your name and address and will be instructed to identify the Announcement number of interest.

Please refer to Announcement Number 98086 when requesting information and submitting an application.

You may obtain this and other CDC Announcements from one of two Internet sites on the actual publication date: CDC's homepage at http://www.cdc.gov or at the Government Printing Office homepage (including free on-line access to the **Federal Register** at http://www.access.gpo.gov.

Potential applicants may obtain a copy of *Healthy People 2000* (Full Report, Stock No. 017–001–00474–0) or *Healthy People 2000* (Summary Report, Stock No. 017–001–00473–1) referenced in the Introduction through the Superintendent of Documents, Government Printing Office, Washington, DC 20402–9325; telephone 202–512–1800.

Dated: June 22, 1998.

John L. Williams,

Director, Procurement and Grants Office, Centers for Disease Control and Prevention (CDC).

[FR Doc. 98–17202 Filed 6–26–98; 8:45 am]

BILLING CODE 4163–18–U

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

The National Center for Infectious Diseases (NCID), Hepatitis Branch of the Centers for Disease Control and Prevention (CDC) Announces the Following Meeting

Name: Consultants Meeting on the Prevention and Control of Hepatitis C Virus (HCV) Infection.

Times and Dates: 6 p.m.–9:30 p.m., July 15, 1998. 8 a.m.-5 p.m., July 16, 1998. 8 a.m.–12 p.m., July 17, 1998.

Place: Atlanta Marriott Marquis Hotel, 265 Peachtree Center Avenue, Atlanta, Georgia 30303.

Status: Open to the public, limited only by the space available. Registration is required.

Purpose: The purpose of this working meeting is to review and discuss draft recommendations that will serve as a resource to individuals and organizations involved in evaluating persons for HCV infection, and are based on currently available knowledge.

Matters To Be Discussed: Participants will discuss recommendations for identifying persons at risk for HCV infection and the appropriate counseling and testing of these persons. Participants will also discuss recommendations to guide appropriate medical referral of HCV infected persons. The agenda will include an overview of HCV public health strategies; and sessions on (a) screening; (b) counseling and referral; and (c) implementation.

The participants will include representatives from public, private, voluntary and non-governmental organizations.

Agenda items are subject to change as priorities dictate.

Written comments are welcome and should be received by the contact person listed below prior to the opening of the meeting.

Contact Person for More Information: Wesley Hodgson, Hepatitis Branch, NCID, CDC, M/S G–37, 1600 Clifton Road, NE, Atlanta, Georgia 30333, telephone 404/639–3048, fax 404/639–1538, e-mail wxh9@cdc.gov.

Dated: June 23, 1998.

Carolyn J. Russell,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC).

[FR Doc. 98–17203 Filed 6–26–98; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Antiviral Drugs Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). At least one portion of the meeting will be closed to the public.

Name of Committee: Antiviral Drugs Advisory Committee.

General Function of the Committee: To provide advice and recommendations to the agency on FDA's regulatory issues.

Date and Time: The meeting will be held on July 14 and 15, 1998, from 8:30 a.m. to 5 p.m.

Location: Bethesda Holiday Inn, Versailles Ballrooms I and II, 8120 Wisconsin Ave., Bethesda, MD.

Contact Person: Rhonda W. Stover, or John B. Schupp, Center for Drug Evaluation and Research (HFD–21), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–827–7001, or FDA Advisory Committee Information Line, 1–800–741–8138 (301–443–0572 in the Washington, DC area), code 12531. Please call the Information Line for up-to-date information on this meeting.

Agenda: On July 14, 1998, the committee will hear presentations concerning general regulatory issues from the Division of Antiviral Drug Products.

Procedure: On July 14, 1998, from 8:30 a.m. to 1 p.m. the meeting is open to the public. Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person by July 6, 1998. Oral presentations from the public will be scheduled between approximately 11 a.m. and 12 m. on July 14, 1998. Time allotted for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact person before July 6, 1998, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation.

Closed Committee Deliberations: On July 14, 1998, from 1 p.m to 5 p.m., and on July 15 from 8:30 a.m. to 5 p.m., the meeting will be closed to permit discussion and review of trade secret and/or confidential commercial information (5 U.S.C. 552b(c)(4)). The meeting will discuss information relevant to pending investigational new drug applications and drug development plans.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C., app. 2).

Dated: June 22, 1998.

Michael A. Friedman,

Deputy Commissioner for Operations.

[FR Doc. 98–17212 Filed 6-26-98; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Biological Response Modifiers Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). At least one portion of the meeting will be closed to the public.

Name of Committee: Biological Response Modifiers Advisory Committee.

General Function of the Committee: To provide advice and recommendations to the agency on FDA's regulatory issues.

Date and Time: The meeting will be held on July 30, 1998, 8 a.m. to 6 p.m.

Location: Bethesda Holiday Inn, Versailles Ballrooms I and II, 8120 Wisconsin Ave., Bethesda, MD.

Contact Person: Gail M. Dapolito or Rosanna L. Harvey, Center for Biologics Evaluation and Research (HFM–211), Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852, 301–827–0314, or FDA Advisory Committee Information Line, 1–800–741–8138 (301–443–0572 in the Washington, DC area), code 12389. Please call the Information Line for up-to-date information on this meeting.

Agenda: The committee will discuss: (1) Biologics license application 97–0509, Amgen Inc.'s Stemgen® (ancestim); (2) the report from the December 17, 1997, meeting of the Xenotransplantation Subcommittee; and (3) the research programs in the Laboratory of Immunology and the Laboratory of Molecular Immunology, Office of Therapeutics Research and Review, Center for Biologics Evaluation and Research. An indication is sought, in combination with Neupogen® (filgrastim), for use in mobilization of peripheral blood progenitor cells.

Procedure: On July 30, 1998, from 8 a.m. to 5 p.m., the meeting is open to the public. Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person by July 20, 1998. Oral presentations from the public will be scheduled between approximately 8 a.m. and 9 a.m. Time allotted for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact person before July 20, 1998, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation.

Closed Committee Deliberations. On July 30, 1998, from 5 p.m. to 6 p.m., the meeting will be closed to permit discussion where disclosure would constitute a clearly unwarranted invasion of personal privacy (5 U.S.C. 552b(c)(6)). The committee will discuss confidential information relevant to the scientific site visit report of the Laboratory of Immunology and the Laboratory of Molecular Immunology, Office of Therapeutics Research and Review, Center for Biologics Evaluation and Research.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).

Dated: June 18, 1998.

Michael A. Friedman,

Deputy Commissioner for Operations.

[FR Doc. 98–17146 Filed 6-26-98; 8:45 am]

BILLING CODE 4160–01–F